The German giant has already trimmed more than 10,000 employees since initiating a massive restructuring initiative in July ...

Maziar Mike Doustdar, who was named as Novo Nordisk’s new CEO last week, spoke on a second quarter earnings call of ...

Terns, once a rising star in obesity and the MASH space, will refocus on cancer and partner out a handful of obesity assets.

President Donald Trump plans to start with a “small tariff” on pharmaceutical imports before ramping duties up to 250% within ...

BioNTech also laid off 63 employees in June in conjunction with the discontinuation of its cell therapy manufacturing ...

George Tidmarsh takes over temporarily at CBER following Vinay Prasad’s abrupt departure; Replimmune trial leaders protest ...

The Department of Health and Human Services is terminating around $500 million in BARDA contracts associated with mRNA ...

While a substantial portion of pipeline assets are externally sourced, many Big Pharmas are tapping into incubators and ...

The regulatory environment is placing extreme pricing pressure on pharmaceutical manufacturers. Their success in the market ...

Out-licensing drugs to multinational corporations is a natural step for Chinese biotechs, but the recent rise in deals is ...

Leslie Zhen Liang is an award-winning investigative health and science journalist with a decade of experience covering ...

From tariffs to drug pricing to the FDA, biopharma CEOs find themselves pulled into policy discussions on this year’s second quarter earnings calls.